Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

Company reaffirms its innovation leadership and long-term commitment to hepatitis research

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The compound, known as SCH 900518 is currently in Phase IIa clinical development. The update was presented today as part of the company's 2008 R&D Update meeting at its headquarters in Kenilworth, N.J.

"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.

The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... 2007 - Advanced Cell,Technology, Inc.'s (OTCBB: ACTC) ability ... Scientific American's March 2007 issue as the,lead story ... of the article,which notes Advanced Cell's ability to ... pigment epithelial (RPE),tissue," is timely as it comes ...
... Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X,announced ... online version of,the journal Blood demonstrated that ... responses against,patient-derived multiple myeloma tumor cells as ... as a combination therapy.,GX15-070 is a small ...
Cached Medicine Technology:Advanced Cell Technology's Ability to Rescue Vision in Blind Rats,Noted in Scientific American 2Advanced Cell Technology's Ability to Rescue Vision in Blind Rats,Noted in Scientific American 3Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 “After my mom’s stroke, ... had a stroke and loss the use of his left side. ... design a way to help people like them enjoy eating again,” ... a prototype for the PATRICIA CAROL HALL PLATE (P C H ... offers a more ergonomic way to eat for individuals who suffer ...
(Date:7/12/2014)... July 12, 2014 Wright & Schulte LLC ... Orthopedics , Inc., a subsidiary of Johnson & Johnson, on ... chronic pain after receiving a metal-on-metal DePuy Pinnacle hip replacement ... remove the artificial hip implant. The DePuy hip lawsuit was ... District of Texas (Case No. 3:14-cv-2427) where DePuy Pinnacle ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
(Date:7/12/2014)... 12, 2014 Floor-grade instrument ... 4.1 out of 5. This above-average score represents ... underpinning buyer negotiation power over the three years ... Son, “during the period, surging demand for healthcare ... with new product development, have placed upward pressure ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress manufacturer and retailer, ... its online category. Furthermore, the firm has announced that ... up to 62% off. , The brand new Quinceanera ... of quality and style. All items in the new ... for the company’s other items: lace evening dresses, short ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... Nov. 8 Synova Healthcare Group,Inc. (OTC Bulletin Board: ... its Today(R) Sponge non-hormonal contraceptive,product in Hong Kong and ... Hong Kong. This represents an important milestone for the,Company, ... made the Today(R) Sponge,available to women outside North America. ...
... Nov. 8, 2007 An Israeli-Jordanian-U.S. cooperative project aimed ... neighboring southern cities of Aqaba in Jordan and Eilat ... Hebrew University of Jerusalem together with scientists from the ... Research Institute of Reno, Nevada, in the US. ...
... determined how cardiac cells die just as emergency treatments restore blood ... puzzled doctors who are able to relieve pain in patients suffering ... renewed rush of blood. , The discovery may lead to ... the stoppage of blood flow and resulting loss of oxygen to ...
... , The topic of cancer prevention is covered ... with apparently conflicting information and complex scientific research that ... The American Association for Cancer Research (AACR) and Susan ... communication between the scientific research community and journalists who ...
... New Law and New Regulations Could Hold the Key to ... Reducing Rising Skin Cancer Rates, NEW YORK, ... of skin cancer will be diagnosed in the United States in,2007. While ... stress that prevention is still the best,medicine. In fact, dermatologists are hopeful ...
... NEW YORK, Nov. 8 The changing of the ... to health clubs for a,healthy dose of indoor exercise. ... beneficial activities a person can do to improve one,s ... the hidden dangers of,exercise -- bothersome skin conditions that ...
Cached Medicine News:Health News:Today(R) Sponge to be Distributed in Hong Kong and Macau 2Health News:Today(R) Sponge to be Distributed in Hong Kong and Macau 3Health News:'Beam of Light' is ray of hope for Israeli-Jordanian cooperation 2Health News:Mitochondria send death signal to cardiac cells, study shows 2Health News:Mitochondria send death signal to cardiac cells, study shows 3Health News:Skin Cancer Prevention Update: 2Health News:Skin Cancer Prevention Update: 3Health News:Skin Cancer Prevention Update: 4Health News:Skin Cancer Prevention Update: 5Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 2Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 3Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 4Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 5
... Combining exceptional new features ... XLTEKs latest innovation, the ... biphasic intracranial stimulation up ... 300 volts and transcranial ...
... high-volume analyzer that builds upon the field-proven ... and the latest Olympus technological advances. The ... with up to 147 on-board chemistries and ... Choose from Olympus 122 test menu, including ...
... e is designed for the ... laboratories and hospitals. Automate and consolidate ... reliability and Olympus 122 test menu, ... specific proteins, esoteric chemistries and tests ...
... is intended for the quantitative determination of Erythropoietin ... for in vitro diagnostic use, as an aid ... the advent of the administration of recombinant erythropoietin ... cell mass, an erythropoietin assay may be used ...
Medicine Products: